2022
DOI: 10.1002/ags3.12604
|View full text |Cite
|
Sign up to set email alerts
|

Differences in prognosis and underuse of adjuvant chemotherapy between elderly and non‐elderly patients in stage III colorectal cancer

Abstract: Aim We aimed to clarify the use of adjuvant chemotherapy and the prognosis of elderly colorectal cancer patients compared with non‐elderly patients, and the usefulness of sarcopenia as an indicator for the introduction and completion of adjuvant chemotherapy. Methods Between 2013 and 2021, 215 patients with pStage III disease were included. We investigated perioperative clinicopathological factors, adjuvant chemotherapy details, and prognosis. Preoperative sarcopenia status was evaluated using computed tomogra… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
28
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 8 publications
(28 citation statements)
references
References 31 publications
0
28
0
Order By: Relevance
“…9,10,12 In addition to FOLFOX, the remaining studies also examined other single-agent or multi-agent chemotherapy regimens that include fluoropyrimidine (capecitabine or 5FU) alone, fluoropyrimidine plus oxaliplatin and non-oxaliplatin-based regimens such as FOLFIRI (folinic acid, 5FU and irinotecan). 11,13,15 Chemotherapy toxicities Chemotherapy toxicity was measured in four studies. 10,12,13,15 Dose-limiting toxicity (DLT) included dose reduction, dose delay, regimen change, treatment discontinuation and incidences of hospitalization were noted in five of the six studies.…”
Section: Chemotherapy Agents Usedmentioning
confidence: 99%
See 4 more Smart Citations
“…9,10,12 In addition to FOLFOX, the remaining studies also examined other single-agent or multi-agent chemotherapy regimens that include fluoropyrimidine (capecitabine or 5FU) alone, fluoropyrimidine plus oxaliplatin and non-oxaliplatin-based regimens such as FOLFIRI (folinic acid, 5FU and irinotecan). 11,13,15 Chemotherapy toxicities Chemotherapy toxicity was measured in four studies. 10,12,13,15 Dose-limiting toxicity (DLT) included dose reduction, dose delay, regimen change, treatment discontinuation and incidences of hospitalization were noted in five of the six studies.…”
Section: Chemotherapy Agents Usedmentioning
confidence: 99%
“…10,12,13,15 Dose-limiting toxicity (DLT) included dose reduction, dose delay, regimen change, treatment discontinuation and incidences of hospitalization were noted in five of the six studies. [9][10][11]13,15 For the four studies that focused on chemotherapy toxicities, the types of toxicities that were recorded included haemotoxicity (neutropenia, thrombocytopenia, anaemia), gastrointestinal toxicity (nausea, vomiting, diarrhoea), neurotoxicity (neuropathy), liver impairment and mucositis. Two of the four studies graded toxicities using the Common Terminology Criteria for Adverse Events (CTCAE) with a particular interest in grade 2 toxicities and above.…”
Section: Chemotherapy Agents Usedmentioning
confidence: 99%
See 3 more Smart Citations